Literature DB >> 17324410

Endoscopic stenting in patients with recurrent malignant obstruction after gastric surgery: uncovered versus simultaneously deployed uncovered and covered (double) self-expandable metal stents.

Geun Am Song1, Dae Hwan Kang, Tae Oh Kim, Jeong Heo, Gwang Ha Kim, Mong Cho, Jeong Ho Heo, Jeong Yeol Kim, Jae Seung Lee, Yeol Jo Jeoung, Tae Yong Jeon, Dong Heon Kim, Mun Sup Sim.   

Abstract

BACKGROUND: Uncovered, rather than covered, metal stents are commonly used for palliation of malignant gastric outlet obstruction because of the low risk of stent migration, but tumor ingrowth risk is a major drawback. Few reports address malignant obstruction after gastric surgery.
OBJECTIVE: Our purpose was to compare the technical feasibility and clinical outcome of using an endoscopic uncovered self-expandable metal stent (SEMS) and simultaneous use of uncovered and covered SEMS (double SEMS) in patients with recurrent malignant obstruction after gastric surgery.
DESIGN: Retrospective study.
SETTING: Tertiary care, academic medical center, from August 2000 to June 2005. PATIENTS: Twenty patients were included in the study. All patients had symptomatic obstruction with nausea, vomiting, and decreased oral intake. INTERVENTION: Ten patients received uncovered SEMS; the other 10 received double SEMS. MAIN OUTCOME MEASUREMENTS: To compare tumor ingrowth and stent patency between the uncovered and the double-SEMS groups.
RESULTS: Technical and clinical successes were 10 of 10 and 8 of 10, respectively, in the uncovered SEMS group and 10 of 10 and 10 of 10, respectively, in the double SEMS group. Six of 10 patients (60%) with uncovered SEMS had tumor ingrowth compared with 1 of 10 patients with double SEMS, P = .057. Five of 10 patients (50%) with uncovered SEMS had very early restenosis, but no patients had early restenosis in the double SEMS group, P = .033. Stent patency was a median of 21.5 days (range, 7-217 days) in the uncovered SEMS group and 150 days (range 29-263 days) in the double SEMS group, P = .037. Survival duration was 109.5 days (range 29-280 days) and 150 days (range 29-263 days), respectively. LIMITATIONS: This was a small retrospective study.
CONCLUSION: Simultaneous double stent placement seems to be technically feasible and effective for palliative treatment of recurrent malignant obstruction after gastric surgery. Double stent placement is important in preventing tumor ingrowth, especially very early restenosis, and prolongs stent patency. We suggest that this procedure be considered rather than uncovered stent alone as the primary choice for palliation of obstruction in such patients.

Entities:  

Mesh:

Year:  2007        PMID: 17324410     DOI: 10.1016/j.gie.2006.08.030

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  14 in total

1.  Duodenal stenting for malignant gastric outlet obstruction: prospective study.

Authors:  Eduardo Guimarães Hourneaux Moura; Flávio Coelho Ferreira; Spencer Cheng; Diogo Turiani Hourneaux Moura; Paulo Sakai; Bruno Zilberstain
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

2.  Duodenal and colonic stent placement with 0.025″ and 0.035″ guidewires is equally safe and effective.

Authors:  Jessica Chan; Kristen Hilden; John Fang; Douglas G Adler
Journal:  Dig Dis Sci       Date:  2011-10-08       Impact factor: 3.199

3.  Long-term outcome after endoscopic stent therapy for complications after bariatric surgery.

Authors:  Atif Iqbal; Brent Miedema; Archana Ramaswamy; Nicole Fearing; Roger de la Torre; Youngju Pak; Caleb Stephen; Klaus Thaler
Journal:  Surg Endosc       Date:  2010-07-13       Impact factor: 4.584

4.  Self-expandable metallic stent placement for malignant obstruction in patients with locally recurrent gastric cancer.

Authors:  Jaihwan Kim; Il Ju Choi; Chan Gyoo Kim; Jong Yeul Lee; Soo-Jeong Cho; Sook Ryun Park; Jun Ho Lee; Keun Won Ryu; Young-Woo Kim; Young-Iee Park
Journal:  Surg Endosc       Date:  2010-10-26       Impact factor: 4.584

5.  Clinical outcomes of self-expandable metal stents in palliation of malignant anastomotic strictures caused by recurrent gastric cancer.

Authors:  Yu Kyung Cho; Sang Woo Kim; Kwan Woo Nam; Jae Hyuck Chang; Jae Myung Park; Jeong-Jo Jeong; In Seok Lee; Myung-Gyu Choi; In-Sik Chung
Journal:  World J Gastroenterol       Date:  2009-07-28       Impact factor: 5.742

6.  An integrated, self-expanding, Y-shaped, metallic stent for patients with complex obstruction after gastrojejunostomy (Billroth II): initial experience.

Authors:  G Wu; Y-D Li; X-W Han; P-X Ding
Journal:  Radiol Med       Date:  2011-03-19       Impact factor: 3.469

7.  A double-layered (comvi) self-expandable metal stent for malignant gastroduodenal obstruction: a prospective multicenter study.

Authors:  Yong Wuk Kim; Cheol Woong Choi; Dae Hwan Kang; Hyung Wook Kim; Chung Uk Chung; Dong Uk Kim; Su Bum Park; Kee Tae Park; Suk Kim; Eul Jo Jeung; Yong Mok Bae
Journal:  Dig Dis Sci       Date:  2011-01-25       Impact factor: 3.199

8.  Malignant gastric outlet obstructions: treatment with self-expandable metallic stents.

Authors:  Jin Hyoung Kim; Ho-Young Song; Ji Hoon Shin
Journal:  Gut Liver       Date:  2010-09-10       Impact factor: 4.519

9.  Covered Metal Stent after Dysfunction of Uncovered Stents for Palliation of Gastrointestinal Malignant Obstruction.

Authors:  Marta Patita; Rui Castro; Diogo Libânio; Rui Pedro Bastos; Rui Silva; Mário Dinis-Ribeiro; Pedro Pimentel-Nunes
Journal:  GE Port J Gastroenterol       Date:  2020-05-13

Review 10.  Treatment of malignant gastric outlet obstruction with stents: an evaluation of the reported variables for clinical outcome.

Authors:  Lene Larssen; Asle W Medhus; Truls Hauge
Journal:  BMC Gastroenterol       Date:  2009-06-17       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.